The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of:

##STR00001## wherein X is a divalent linking moiety; and R.sup.1-R.sup.10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R.sup.3 or R.sup.8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

A polymerization initiator composition includes isomers of the polymerization initiator, thereby preventing instability and inertness of the polymerization initiator and physical property degradation of the SSBR, minimizing by-products and unreacted materials, and remarkably improving a conversion ratio. In addition, when the polymerization initiator composition according to the present invention is used, there is no need to add a polar additive separately upon polymer polymerization, since the polar additive is already added at the time of preparing the polymerization initiator. Further, the polymer initiator composition has high polarity so that the hydrophobic SSBR and the hydrophilic silica can be effectively dispersed.

A polymerization initiator composition includes isomers of the polymerization initiator, thereby preventing instability and inertness of the polymerization initiator and physical property degradation of the SSBR, minimizing by-products and unreacted materials, and remarkably improving a conversion ratio. In addition, when the polymerization initiator composition according to the present invention is used, there is no need to add a polar additive separately upon polymer polymerization, since the polar additive is already added at the time of preparing the polymerization initiator. Further, the polymer initiator composition has high polarity so that the hydrophobic SSBR and the hydrophilic silica can be effectively dispersed.

A compound represented by the following general formula (I):

##STR00001##

(the symbols in the general formula (I) are as described in the Description), wherein the compound contains one or more structures selected from the following (i) and (ii): (i) A is an aliphatic hydrocarbon group containing two or more alicyclic hydrocarbon groups, containing a saturated aliphatic hydrocarbon group at a terminal position directly bound to N, and optionally containing O, S, N in a carbon chain (ii) at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a cycloalkyl group optionally containing a substituent group or an aryl group optionally containing a substituent group.